Autoimmune Antibody Detection

Autoimmune antibody detection is the laboratory measurement of autoantibodies, immunoglobulins directed against the body's own antigens. These tests support the classification and characterisation of autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and autoimmune thyroid, liver, and neurological disorders.

Definition

Autoantibody detection comprises laboratory assays that identify and quantify antibodies reactive against self-antigens, used as biomarkers in the classification and assessment of autoimmune disease.

Scope

The topic covers the principal methods for detecting autoantibodies, including indirect immunofluorescence, enzyme immunoassays, and multiplex and line-blot assays, and the interpretation of common markers such as antinuclear antibodies and their specific subtypes. It is presented as a reference-and-methods topic, not as a diagnostic protocol.

Core questions

• Which autoantibody specificities are informative for a given suspected autoimmune disease?
• How do screening assays (such as antinuclear antibody immunofluorescence) relate to confirmatory antigen-specific tests?
• How are autoantibody titres and patterns interpreted in light of disease prevalence and assay performance?

Key concepts

• Self-antigen and loss of tolerance
• Antinuclear antibodies (ANA) and immunofluorescence patterns
• Antigen-specific autoantibodies (e.g., anti-dsDNA, anti-CCP, anti-topoisomerase)
• Screening versus confirmatory testing
• Titre and serial measurement
• Sensitivity, specificity, and disease classification criteria

Mechanisms

Autoantibody assays detect antibodies that bind self-antigens. Indirect immunofluorescence on cultured cell substrates screens for antinuclear antibodies and reveals staining patterns that suggest particular target antigens. Solid-phase immunoassays, line blots, and multiplex bead assays then identify specific antibody specificities, such as anti-double-stranded DNA in lupus or anti-cyclic citrullinated peptide in rheumatoid arthritis. Results are reported as titres or quantitative units against defined reference ranges; their meaning depends on the assay's analytic performance and the prior probability of the disease being evaluated.

Clinical relevance

Specific autoantibodies are embedded in international disease-classification criteria: anti-nuclear and anti-dsDNA antibodies feature in the 2019 EULAR/ACR lupus criteria, and anti-centromere and anti-topoisomerase antibodies in the 2013 systemic sclerosis criteria. The entry describes how these markers are measured and how classification frameworks use them at a population level; it does not provide individual diagnostic rules.

Epidemiology

Low-titre antinuclear antibodies occur in a proportion of healthy individuals and rise with age, so positivity is interpreted in the context of pre-test probability. Antigen-specific autoantibodies are generally rarer and more disease-associated, which is why screening results are confirmed with specific assays before being weighted heavily.

Evidence & guidelines

Autoantibody testing is governed by disease-classification criteria from EULAR/ACR and by laboratory-standardisation efforts that define reference methods, units, and reporting conventions for assays such as antinuclear and anti-dsDNA antibody testing. These frameworks specify which specificities are recommended and how their results should be interpreted within a wider clinical picture.

History

Autoantibody detection began with the discovery of the LE cell phenomenon and the subsequent introduction of immunofluorescence-based antinuclear antibody testing in the mid-twentieth century. Identification of antigen-specific autoantibodies and the move to standardised, automated immunoassays progressively refined the field, and successive disease-classification criteria have incorporated these markers.

Debates

How should antinuclear antibody screening be standardised across methods?

Immunofluorescence and solid-phase immunoassays can give discordant results, and reconciling screening method, titre reporting, and pattern interpretation across laboratories remains an active standardisation question.

Seminal works

• aringer-2019
• vandenhoogen-2013

Frequently asked questions

What is an antinuclear antibody (ANA) test?

It is a screening assay that detects antibodies directed against nuclear self-antigens; a positive screen is typically followed by antigen-specific tests to identify the particular antibody and its disease associations.

Does a positive autoantibody result mean a person has an autoimmune disease?

Not on its own. Some autoantibodies occur in healthy people, especially at low titre, so results are interpreted together with clinical features and classification criteria.